论文部分内容阅读
目的探讨甘精胰岛素联用格列美脲治疗2型糖尿病患者的疗效及安全性。方法 64例2型糖尿病患者随机分为甘精胰岛素治疗组(GL组)和中性鱼精蛋白锌胰岛素(NPH)组,予睡前皮下注射胰岛素联合口服格列美脲治疗12周,观察12周前后空腹血糖、餐后2h血糖、糖化血红蛋白、空腹C肽、餐后C肽的变化。结果 GL组治疗后FPG(7.1±0.4)mmol/L,2hPG(8.8±1.4)mmol/L,HbA1c(6.7±0.3)%;NPH组治疗后FPG(6.8±0.8)mmol/L,2hPG(8.8±1.2)mmol/L,HbAlc(6.9±0.4)%,较治疗前差异有统计学意义(P<0.01);但GL组的低血糖事件明显少于NPH组(P<0.05)。结论甘精胰岛素联用格列美脲治疗2型糖尿病的方案安全有效。
Objective To investigate the efficacy and safety of glargine combined with glimepiride in the treatment of type 2 diabetes mellitus. Methods Sixty-four patients with type 2 diabetes were randomly divided into insulin glargine treatment group (GL group) and neutral protamine zinc insulin (NPH) group. The patients were treated with subcutaneous insulin and glimepiride for 12 weeks before bedtime, and 12 Fasting blood glucose before and after 2h, postprandial blood glucose 2h, glycosylated hemoglobin, fasting C-peptide, postprandial C-peptide changes. Results FPG (7.1 ± 0.4) mmol / L, 2 hPG (8.8 ± 1.4) mmol / L and HbA1c (6.7 ± 0.3)% in GL group were significantly higher than those in NPH group ± 1.2) mmol / L and HbAlc (6.9 ± 0.4)%, respectively, compared with that before treatment (P <0.01). However, the incidence of hypoglycemia in GL group was significantly less than that in NPH group (P <0.05). Conclusion Glargine and glimepiride in the treatment of type 2 diabetes are safe and effective.